Boston Scientific CorporationBSX

Healthcare
Neutral

ASignal's systematic analysis rates BSX as Neutral. Boston Scientific Corporation has a market cap of $69.46B, a P/E of 18.62, a 17.5% net margin, and 7.5% year-over-year revenue growth.

Reflects the latest available analysis · analyzed Aug 1, 2026

The case on BSX

Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.

Bull case
  • Forward P/E of 13.54x suggests valuation discount relative to growth (PEG ratio 0.57x)
  • Strong gross margin of 69.28% indicates pricing power and cost control
  • Operating margin of 23.91% reflects efficient operations
  • Debt-to-equity ratio of 0.42x is below 0.5 threshold, indicating solid financial health
  • Earnings growth of 15.1% year-over-year shows accelerating profitability
  • MACD histogram is expanding positively, signaling strengthening momentum
VS
Bear case
  • Current RSI at 60.9 is approaching overbought territory, limiting near-term upside
  • Price trading near upper Bollinger Band (46.89) suggests potential short-term resistance
  • Return on equity and return on assets are unavailable, limiting fundamental insight
  • Operating cash flow and free cash flow data missing, reducing confidence in earnings quality
  • Low Reddit mentions (1) indicates limited retail investor interest or scrutiny

Key facts

Sector
Healthcare
Market cap
$69.46B
P/E ratio
18.62
Gross margin
69.3%
Net margin
17.5%
Rev growth YoY
7.5%
Price (Aug 1, 2026)
$46.73

Peers

Clustered with BSX by analysis-profile similarity.

Subscriber-only

See the full verdict on BSX

ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.

How ASignal analyzes BSX

Most investors never get a second opinion, let alone several. ASignal runs BSX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.

The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.

Boston Scientific Corporation (BSX) Stock Analysis - ASignal rates it Neutral